Annamaria Ruzzo |
High Let-7a MicroRNA Levels in KRAS-Mutated Colorectal Carcinomas May Rescue Anti-EGFR Therapy Effects in Patients with Chemotherapy-Refractory Metastatic Disease. |
2012 |
3 |
10.1634/theoncologist.2012-0081 |
Emily Hannah Crowley |
Targeted Knock-in of the Polymorphism rs61764370 Does Not Affect KRAS Expression but Reduces let-7 Levels. |
2013 |
1 |
10.1002/humu.22487 |
Robert Pilarski |
The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer. |
2012 |
2 |
10.1371/journal.pone.0037891 |
Paul Pharoah |
Association between KRAS rs61764370 and triple-negative breast cancer--a false positive? |
2011 |
1 |
- |
Antoinette Hollestelle |
Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families. |
2011 |
8 |
10.1007/s10549-010-1080-z |
A Berchuck |
Association of KRAS SNP rs61764370 with risk of invasive epithelial ovarian cancer: Implications for clinical testing |
2011 |
2 |
10.1016/j.ygyno.2011.02.028 |
E Ratner |
The KRAS variant is at an increased prevalence in type 2 endometrial cancers |
2010 |
1 |
|
Trupti Paranjape |
A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. |
2011 |
16 |
10.1016/S1470-2045(11)70044-4 |
P D P Pharoah |
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: Implications for clinical testing |
2011 |
1 |
|
Paul D P Pharoah |
The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing |
2011 |
1 |
10.1158/1078-0432.CCR-10-3405 |
Ana Sebio |
The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients |
2013 |
1 |
10.1097/FPC.0b013e32835d9b0b |
G. Tonini |
High Let-7a MicroRNA Levels in KRAS-Mutated Colorectal Carcinomas May Rescue Anti-EGFR Therapy Effects in Patients with Chemotherapy-Refractory Metastatic Disease |
2012 |
5 |
10.1634/theoncologist.2012-0081 |
Paul D P Pharoah |
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. |
2011 |
2 |
- |
P D Pharoah |
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing |
2011 |
1 |
1078-0432.CCR-10-3405 [pii]\r10.1158/1078-0432.CCR-10-3405 |
Jasmina-Ziva Cerne |
KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study |
2012 |
5 |
10.1186/1471-2407-12-105 |
P D P Pharoah |
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. |
2011 |
12 |
- |
Paul D P Pharoah |
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. |
2011 |
1 |
10.1158/1078-0432.CCR-10-3405 |
Elena Ratner |
A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. |
2010 |
26 |
- |
E Caiola |
KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer |
2012 |
5 |
- |
Trupti Paranjape |
A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. |
2011 |
16 |
- |
Hien T T Luong |
No evidence for genetic association with the let-7 microRNA-binding site or other common KRAS variants in risk of endometriosis. |
2012 |
5 |
10.1093/humrep/des329 |
Paul D P Pharoah |
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. |
2011 |
9 |
10.1158/1078-0432.CCR-10-3405 |
J B Weidhaas |
MicroRNA binding site SNPs and lung cancer risk |
2010 |
1 |
- |
P D Pharoah |
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing |
2011 |
2 |
10.1158/1078-0432.CCR-10-3405 |
Elena Ratner |
A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. |
2010 |
29 |
10.1158/0008-5472.CAN-10-0689 |
P. D. P. Pharoah |
The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing |
2011 |
1 |
10.1158/1078-0432.CCR-10-3405 |
J B Weidhaas |
MicroRNA binding site SNPs and lung cancer risk |
2010 |
1 |
|
Robert Pilarski |
The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer. |
2012 |
1 |
10.1371/journal.pone.0037891 |
T Paranjape |
A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis |
2011 |
2 |
S1470-2045(11)70044-4 [pii]\r10.1016/S1470-2045(11)70044-4 |
Jasmina-Ziva Cerne |
KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study |
2012 |
3 |
|
H T Luong |
No evidence for genetic association with the let-7 microRNA-binding site or other common KRAS variants in risk of endometriosis |
2012 |
2 |
10.1093/humrep/des329 |
Ana Sebio |
The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients. |
2013 |
4 |
10.1097/FPC.0b013e32835d9b0b |
Antoinette Hollestelle |
Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families. |
2011 |
6 |
- |
P D Pharoah |
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing |
2011 |
1 |
10.1158/1078-0432.CCR-10-3405 |
Elisa Caiola |
KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer. |
2012 |
6 |
|